PE
VRNA

Point72 Europe’s Verona Pharma VRNA Stock Holding History

Point72 Europe’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,500
Closed -$4.02M – 786
2025
Q2 		$4.02M Buy
42,500
+4,365
+11% +$323K 0.16% 108
2025
Q1 		$2.42M Sell
38,135
-1,234
-3% -$73.8K 0.17% 107
2024
Q4 		$1.83M Buy
+39,369
New +$1.48M 0.11% 110

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Europe's VRNA Position: Q3 2025 in Review

Point72 Europe sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 42,500 shares — an estimated $4.02M sold.

Point72 Europe first reported a position in VRNA in Q4 2024 and held it in 3 quarters. The position peaked at $4.02M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Point72 Europe reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Point72 Europe sold 42,500 Verona Pharma shares in Q3 2025, an estimated $4.02M.
  • Point72 Europe first reported a position in Verona Pharma in Q4 2024 and held it in 3 quarters.
  • Point72 Europe's Verona Pharma position peaked at $4.02M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.